A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

✍ Scribed by Taimur Sher; Sikander Ailawadhi; Kena C. Miller; Debbie Manfredi; Margaret Wood; Wei Tan; Gregory Wilding; Myron S. Czuczman; Francisco J. Hernandez-Ilizaliturri; Fredrick Hong; Raman Sood; Saif Soniwala; William Lawrence; Saad Jamshed; Aisha Masood; Daniel Iancu; Kelvin Lee; Asher Chanan-Khan

• Book ID: 108677284
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 130 KB
• Volume: 154
• Category: Article
• ISSN: 0007-1048
• DOI: 10.1111/j.1365-2141.2011.08703.x